Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022

25 May 2022

Leuven, Belgium, Boston, MA, US May 25, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, held its extraordinary shareholders' meeting on May 24, 2022. The shareholders approved all items on the agenda of the extraordinary shareholders' meeting. 

All documents pertaining to this extraordinary shareholders’ meeting, can be consulted on Oxurion’s website Oxurion/shareholders. 

Press release attachment: 
Regulated information